Suppr超能文献

Boston 角膜型 I 号假体的长期疗效:中国人民解放军总医院的经验。

Long-term outcomes of Boston keratoprosthesis type I: the Chinese People's Liberation Army General Hospital experience.

机构信息

Department of Ophthalmology, General Hospital of People's Liberation Army, Beijing, China

Department of Ophthalmology, General Hospital of People's Liberation Army, Beijing, China.

出版信息

Br J Ophthalmol. 2022 Jun;106(6):781-785. doi: 10.1136/bjophthalmol-2019-315617. Epub 2021 Mar 5.

Abstract

PURPOSE

To report the long-term outcomes of Boston keratoprosthesis type I (B-KPro type I) implantation in the management of severe ocular surface disorders.

METHODS

Retrospective case series. Patients who underwent B-KPro type I implantation at the People's Liberation Army General Hospital were enrolled between March 2011 and September 2019. Data regarding visual acuity (VA), B-KPro type I retention and postoperative complications were recorded and analysed.

RESULTS

A total of 103 eyes of 100 patients who underwent B-KPro type I implantation were included. The main indications were chemical burn (59.2%), ocular trauma (25.2%), herpetic keratitis (11.7%) and autoimmune diseases (3.9%). The percentage of eyes with postoperative VA of 10/200 or better was 82.7% at 6 months, 82.8% at 12 months, 77.9% at 2 years, 72.4% at 3 years, 71.1% at 4 years, 69.4% at 5 years, 58.9% at 6 years, 56.8% at 7 years and 42.9% at 8 years. Preoperatively, 8.7% eyes were diagnosed with new-onset glaucoma. Retroprosthetic membrane formation occurred in 19.4% eye. Corneal melting occurred in 18.4% eyes. Sterile vitritis was diagnosed in 4.9% eyes and infectious endophthalmitis in 2.9% eyes. Retinal detachment occurred in 0.9% eyes.

CONCLUSIONS

In a Chinese patient group, B-KPro type I is a viable option for treating severe ocular surface disorders in eyes where conventional keratoplasty would have a poor prognosis, especially in patients with chemical and thermal burns. Improved visual outcomes and high retention rate can be achieved and maintained in most cases.

摘要

目的

报告 Boston 角膜型Ⅰ号(B-KPro Ⅰ型)在治疗严重眼表疾病中的长期疗效。

方法

回顾性病例系列研究。2011 年 3 月至 2019 年 9 月,在解放军总医院行 B-KPro Ⅰ型植入术的患者纳入本研究。记录并分析患者的视力(VA)、B-KPro Ⅰ型保留情况和术后并发症等数据。

结果

共纳入 100 例 103 眼行 B-KPro Ⅰ型植入术的患者。主要适应证为化学烧伤(59.2%)、眼外伤(25.2%)、单纯疱疹病毒性角膜炎(11.7%)和自身免疫性疾病(3.9%)。术后 6 个月、12 个月、2 年、3 年、4 年、5 年、6 年、7 年和 8 年时,VA 达 10/200 或以上的眼比例分别为 82.7%、82.8%、77.9%、72.4%、71.1%、69.4%、58.9%、56.8%和 42.9%。术前,8.7%的眼新诊断为开角型青光眼。19.4%的眼发生后弹力层膨出。18.4%的眼发生角膜融解。4.9%的眼诊断为无菌性眼内炎,2.9%的眼诊断为感染性眼内炎。0.9%的眼发生视网膜脱离。

结论

在中国患者人群中,B-KPro Ⅰ型是治疗常规角膜移植预后较差的严重眼表疾病的可行选择,尤其适用于化学性和热烧伤患者。大多数患者可获得并维持良好的视力结果和高 B-KPro Ⅰ型保留率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验